Antibody-Drug Conjugates – Catalysts For Chemistry

Antibody-drug conjugates (ADCs), also known as "armed antibodies," are poised to revolutionize cancer treatment. These innovative drugs combine the targeting power of antibodies with the potent cell-killing ability of cytotoxic drugs.

An ADC consists of an antibody that seeks out a specific protein on the surface of cancer cells. Once attached, the entire ADC is engulfed by the cancer cell. Inside the cell, the cytotoxic payload is released, destroying the cancer cell from within. This targeted approach offers the potential for fewer side effects compared to traditional chemotherapy.

However, ADCs are complex molecules requiring collaboration across various scientific disciplines. Their large size and intricate structure pose challenges in manufacturing, analysis, and especially linker design. Linkers are crucial components that attach the cytotoxic payload to the antibody. Their properties determine how effectively the drug is delivered inside the cancer cell.

These complexities make ADCs prime candidates for outsourcing to specialized contract research organizations (CROs) with extensive experience. Curia offers a comprehensive suite of services, from payload discovery to preclinical studies and even cGMP manufacturing for clinical trials. Our expertise extends beyond discovery, encompassing development all the way to drug product manufacturing and fill-finish.

This white paper delves deeper into the complexities of linker development and what to consider when choosing a CRO partner for your ADC journey.